Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1988 February; 57(2): 205–212.
PMCID: PMC2246441

The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.


The 'unopposed oestrogen hypothesis' for endometrial cancer maintains that risk is increased by exposure to endogenous or exogenous oestrogen that is not opposed simultaneously by a progestagen, and that this increased risk is due to the induced mitotic activity of the endometrial cells. Investigation of the mitotic rate during the menstrual cycle shows that increases in plasma oestrogen concentration above the relatively low levels of the early follicular phase do not produce any further increase in the mitotic rate of endometrial cells. A modification of the unopposed oestrogen hypothesis which includes this upper limit in the response of endometrial cells to oestrogen is consistent with the known dose-effect relationships between endometrial cancer risk and both oestrogen replacement therapy and postmenopausal obesity; it also suggests that the mechanism by which obesity increases risk in premenopausal women involves progesterone deficiency rather than oestrogen excess, and that the protective effect of cigarette smoking may be greater in postmenopausal than in premenopausal women. Detailed analysis of the age-incidence curve for endometrial cancer in the light of this hypothesis suggests that there will be lifelong effects of even short duration use of exogenous hormones. In particular, 5 years of combination-type oral contraceptive use is likely to reduce a woman's lifetime risk of endometrial cancer by some 60%; whereas 5 years of unopposed oestrogen replacement therapy is likely to increase her subsequent lifetime risk by at least 90%; and even 5 years of 'adequately' opposed therapy is likely to increase subsequent lifetime risk by at least 50%.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974 Jan;3(1):69–96. [PubMed]
  • Baron JA. Smoking and estrogen-related disease. Am J Epidemiol. 1984 Jan;119(1):9–22. [PubMed]
  • Baron JA, Byers T, Greenberg ER, Cummings KM, Swanson M. Cigarette smoking in women with cancers of the breast and reproductive organs. J Natl Cancer Inst. 1986 Sep;77(3):677–680. [PubMed]
  • Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol. 1986 Sep;124(3):434–441. [PubMed]
  • Davidson BJ, Gambone JC, Lagasse LD, Castaldo TW, Hammond GL, Siiteri PK, Judd HL. Free estradiol in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab. 1981 Mar;52(3):404–408. [PubMed]
  • Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst. 1977 Oct;59(4):1055–1060. [PubMed]
  • Ferenczy A, Bertrand G, Gelfand MM. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol. 1979 Apr 15;133(8):859–867. [PubMed]
  • Friedman AJ, Ravnikar VA, Barbieri RL. Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil Steril. 1987 Mar;47(3):398–401. [PubMed]
  • Gambrell RD., Jr The role of hormones in the etiology and prevention of endometrial cancer. Clin Obstet Gynaecol. 1986 Dec;13(4):695–723. [PubMed]
  • Geola FL, Frumar AM, Tataryn IV, Lu KH, Hershman JM, Eggena P, Sambhi MP, Judd HL. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab. 1980 Sep;51(3):620–625. [PubMed]
  • Hartz AJ, Rupley DC, Rimm AA. The association of girth measurements with disease in 32,856 women. Am J Epidemiol. 1984 Jan;119(1):71–80. [PubMed]
  • Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982 Aug;42(8):3232–3239. [PubMed]
  • Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. Br J Cancer. 1983 Jun;47(6):749–756. [PMC free article] [PubMed]
  • Horwitz RI, Feinstein AR. Estrogens and endometrial cancer. Responses to arguments and current status of an epidemiologic controversy. Am J Med. 1986 Sep;81(3):503–507. [PubMed]
  • Jensen J, Christiansen C, Rødbro P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med. 1985 Oct 17;313(16):973–975. [PubMed]
  • Judd HL, Lucas WE, Yen SS. Serum 17 beta-estradiol and estrone levels in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab. 1976 Aug;43(2):272–278. [PubMed]
  • Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Mostow ED, Schwartz PE, O'Connor T, White C. A case-control study of cancer of the endometrium. Am J Epidemiol. 1982 Aug;116(2):333–342. [PubMed]
  • La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst. 1984 Sep;73(3):667–671. [PubMed]
  • Lawrence C, Tessaro I, Durgerian S, Caputo T, Richart R, Jacobson H, Greenwald P. Smoking, body weight, and early-stage endometrial cancer. Cancer. 1987 May 1;59(9):1665–1669. [PubMed]
  • Lesko SM, Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Strom B, Schottenfeld D, Rosenshein NB, Knapp RC, Lewis J, et al. Cigarette smoking and the risk of endometrial cancer. N Engl J Med. 1985 Sep 5;313(10):593–596. [PubMed]
  • Levi F, la Vecchia C, Decarli A. Cigarette smoking and the risk of endometrial cancer. Eur J Cancer Clin Oncol. 1987 Jul;23(7):1025–1029. [PubMed]
  • Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, Brown SE. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976 Jun 3;294(23):1262–1267. [PubMed]
  • MacMahon B, Trichopoulos D, Cole P, Brown J. Cigarette smoking and urinary estrogens. N Engl J Med. 1982 Oct 21;307(17):1062–1065. [PubMed]
  • McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD, Jr, Kurland LT. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol. 1977 Mar 15;127(6):572–580. [PubMed]
  • Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med. 1986 Nov 20;315(21):1305–1309. [PubMed]
  • Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst. 1980 Sep;65(3):559–569. [PubMed]
  • Moore JW, Clark GM, Takatani O, Wakabayashi Y, Hayward JL, Bulbrook RD. Distribution of 17 beta-estradiol in the sera of normal British and Japanese women. J Natl Cancer Inst. 1983 Oct;71(4):749–754. [PubMed]
  • Pardridge WM. Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab. 1986 May;15(2):259–278. [PubMed]
  • Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature. 1983 Jun 30;303(5920):767–770. [PubMed]
  • ROGERS J, MITCHELL GW., Jr The relation of obesity to menstrual disturbances. N Engl J Med. 1952 Jul 10;247(2):53–55. [PubMed]
  • Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL, Jr, Knapp RC, Stolley PD, Schottenfeld D. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985 Oct 17;313(16):969–972. [PubMed]
  • Sherman BM, Korenman SG. Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab. 1974 Jul;39(1):145–149. [PubMed]
  • Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res. 1978 Nov;38(11 Pt 2):4360–4366. [PubMed]
  • Thorneycroft IH, Mishell DR, Jr, Stone SC, Kharma KM, Nakamura RM. The relation of serum 17-hydroxyprogesterone and estradiol-17-beta levels during the human menstrual cycle. Am J Obstet Gynecol. 1971 Dec 1;111(7):947–951. [PubMed]
  • Tyler CW, Jr, Webster LA, Ory HW, Rubin GL. Endometrial cancer: how does cigarette smoking influence the risk of women under age 55 years having this tumor? Am J Obstet Gynecol. 1985 Apr 1;151(7):899–905. [PubMed]
  • Weiss NS, Szekely DR, English DR, Schweid AI. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA. 1979 Jul 20;242(3):261–264. [PubMed]
  • Weiss NS, Farewall VT, Szekely DR, English DR, Kiviat N. Oestrogens and endometrial cancer: effect of other risk factors on the association. Maturitas. 1980 Oct;2(3):185–190. [PubMed]
  • Whitehead MI. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas. 1978 Sep;1(2):87–98. [PubMed]
  • Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981 Dec 31;305(27):1599–1605. [PubMed]
  • Whitehead MI, Townsend PT, Pryse-Davies J, Ryder T, Lane G, Siddle NC, King RJ. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med. 1982 Aug;27(8 Suppl):539–548. [PubMed]
  • Willett WC, Browne ML, Bain C, Lipnick RJ, Stampfer MJ, Rosner B, Colditz GA, Hennekens CH, Speizer FE. Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol. 1985 Nov;122(5):731–740. [PubMed]
  • Zumoff B. Relationship of obesity to blood estrogens. Cancer Res. 1982 Aug;42(8 Suppl):3289s–3294s. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK